Business Context and Reporting Period
Company: Whitehawk Therapeutics, Inc. (formerly Aadi Bioscience, Inc.)
Reporting Period: Quarter ended June 30, 2025 (Q2 2025)
Status: Preclinical-stage oncology therapeutics company.
Key Strategic Shift: The Company divested its legacy commercial business, FYARRO (nab-sirolimus), on March 25, 2025, to KAKEN Investments Inc. for $102.4 million. Following this divestiture, the Company has no approved products and is focused on developing a portfolio of three in-licensed next-generation antibody drug conjugates (ADCs) targeting MUC16, PTK7, and SEZ6, licensed from WuXi Biologics.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $0 | $6,179 | $7,145 | $11,532 |
| Net (Loss) Income | $(52,615) | $(14,583) | $20,401 | $(32,872) |
| Operating Expenses | $54,749 | $21,763 | $77,112 | $46,628 |
| Research & Development | $48,809 | $13,093 | $57,597 | $26,686 |
| Cash & Short-Term Investments | $177,200 | $41,203 | $177,200 | $41,203 |
| Accumulated Deficit | $(312,253) | $(301,835) | $(312,253) | $(301,835) |
Note: YTD 2025 Net Income includes a one-time gain of $87.4 million from the FYARRO divestiture. Without this gain, the Company would have reported a net loss for the period.
Material Changes vs. Prior Period
- Revenue Elimination: Product sales dropped to $0 in Q2 2025 compared to $6.2 million in Q2 2024 due to the March 2025 divestiture of the FYARRO business.
- Significant R&D Increase: R&D expenses surged to $48.8 million in Q2 2025 (up from $13.1 million in Q2 2024). This increase is primarily driven by a $38.0 million upfront license fee payment to WuXi Biologics for the ADC portfolio.
- Balance Sheet Transformation: Total assets increased from $70.3 million (Dec 31, 2024) to $180.8 million (June 30, 2025). This reflects the receipt of $102.4 million in cash from the divestiture and $100.0 million in proceeds from a March 2025 PIPE financing, offset by the removal of FYARRO-related assets (inventory, receivables).
- Share Count Expansion: Outstanding shares increased from 24.7 million (Dec 31, 2024) to 47.1 million (June 30, 2025) due to the issuance of common stock and pre-funded warrants in the 2024/2025 PIPE financing.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash, cash equivalents, and short-term investments of $177.2 million are sufficient to fund operations into 2028.
- Development Timeline: The Company anticipates submitting Investigational New Drug (IND) applications for its three ADC candidates (HWK-007, HWK-016, HWK-206) to the FDA by mid-2026.
- Future Revenue: The Company does not expect to generate product revenue for the foreseeable future as it transitions to a preclinical pipeline.
- Key Risks:
- Regulatory Approval: No guarantee that the ADC candidates will achieve regulatory approval or demonstrate safety/efficacy in clinical trials.
- Third-Party Reliance: Heavy reliance on WuXi Biologics (China-based) for manufacturing and supply, exposing the Company to geopolitical risks and potential U.S. legislation (e.g., BIOSECURE Act).
- Capital Requirements: Continued need for additional financing to support clinical development; failure to raise capital could force program delays.
Investor Verification Checklist
- Divestiture Accounting: Verify the $87.4 million gain on sale of FYARRO is correctly classified as a non-operating item and does not mask ongoing operational losses.
- License Fee Allocation: Confirm the treatment of the $44.0 million total upfront payments to WuXi Biologics ($6M in late 2024, $38M in Q2 2025) and whether any portion is capitalized versus expensed.
- Capital Runway: Assess the burn rate post-divestiture (excluding the one-time gain) to validate the "into 2028" liquidity claim given the high R&D spend.
- Geopolitical Exposure: Evaluate the specific risks associated with the BIOSECURE Act and U.S.-China trade relations regarding the reliance on WuXi Biologics for the entire ADC pipeline.
- Dilution Impact: Review the terms of the outstanding pre-funded warrants (approx. 22 million shares) and their potential impact on future earnings per share.